Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells 31,348 Shares of Stock

Key Points

• Twist Bioscience CEO Emily Leproust sold 31,348 shares of the company's stock for approximately $1 million, reducing her holdings by 4.96% to 601,212 shares.
• Twist Bioscience's stock rose by 5.4% during trading hours, bringing it to $32.79, with a market cap of $1.98 billion.
• Analysts have mixed opinions on Twist Bioscience's stock, with ratings ranging from "buy" to "sell," and a consensus target price of $48.50.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 31,348 shares of the company's stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $1,009,092.12. Following the completion of the transaction, the chief executive officer owned 601,212 shares of the company's stock, valued at approximately $19,353,014.28. The trade was a 4.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Twist Bioscience Stock Up 5.4%

Shares of Twist Bioscience stock traded up $1.67 during trading hours on Wednesday, hitting $32.79. The company had a trading volume of 2,438,969 shares, compared to its average volume of 1,273,207. The company's 50-day moving average is $27.76 and its two-hundred day moving average is $32.84. Twist Bioscience Corporation has a twelve month low of $24.07 and a twelve month high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The company has a market cap of $1.98 billion, a P/E ratio of -22.61 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on TWST shares. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday. Evercore ISI reduced their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Barclays reduced their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research report on Thursday, October 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average target price of $48.50.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of the company. Osaic Holdings Inc. increased its holdings in shares of Twist Bioscience by 31.6% in the 2nd quarter. Osaic Holdings Inc. now owns 7,054 shares of the company's stock valued at $261,000 after purchasing an additional 1,694 shares in the last quarter. Squarepoint Ops LLC increased its holdings in shares of Twist Bioscience by 192.8% in the 2nd quarter. Squarepoint Ops LLC now owns 71,708 shares of the company's stock valued at $2,638,000 after purchasing an additional 47,221 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at about $97,000. Soleus Capital Management L.P. purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at about $13,038,000. Finally, Man Group plc increased its holdings in shares of Twist Bioscience by 5.3% in the 2nd quarter. Man Group plc now owns 106,509 shares of the company's stock valued at $3,918,000 after purchasing an additional 5,348 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.